Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to ...

Disitamab vedotin has shown antitumor activity in HER2-expressing subgroups with pretreated, locally advanced unresectable or metastatic urothelial cancer.

Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

In the UNITE (Urothelial Cancer Network to Investigate Therapeutic Experiences) study, researchers looked at the experience with enfortumab vedotin (EV, Padcev) in patient subsets for which activity ...

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous hematopoietic stem-cell transplantation (HSCT) resulted in improved outcomes in patients with high-risk relapsed ...

Two Sealed Airtight Medical Vials Against Bright Background Front View. Enfortumab vedotin plus pembrolizumab improved survival outcomes, when compared to chemotherapy, in patients with previously ...

Please provide your email address to receive an email when new articles are posted on . The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among ...

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse In Cohort K of the EV-103 phase Ib/II study, ...